MedTrace Logo

Five-Year Observation of Remicade Treatment for Plaque Psoriasis in Austria (Study P04900)

NCT00725452 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2015-07-28

Study results available
· View outcomes & findings →

Summary

Prospective, open-label-, 1-arm, multicenter observational study to determine the dose and interval of Infliximab infusions for subjects with plaque psoriasis.

Conditions

Interventions

BIOLOGICAL

Infliximab

Infliximab initial induction therapy consisting of 3 Infliximab infusions at weeks 0, 2, and 6 given in specialized centers. A maximum of 6 maintenance infusions will be given in doses and intervals due to the discretion of the physicians.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2010-06-30
Completion
2010-06-30

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00725452 on ClinicalTrials.gov